

Pa Ha e bac MC MS

Med ca Hea Off ce

Ce a Va c e l a d

- 62*P(''),*V CON12*4"<"-><>(,M**
- 526:*>#$)('',(*V -")J(*>#$)('',(*>#*")(''*CN1IM*
- 526:*)"<(*Y*Z*B(-%=*"'()"J(*4%)*)(J>%#M
-

- Y*52NC2*HG*'›,›<,*#%#N4"<"-*%'().%,(*4%)*("$A*)($%).(.*4"<"-›<PM
- Y*(\&"-*#&;B()*%4*#%#N4"<"-*<A"<*.%*#%<*$%;(*<%*(;()J(#$P*"#.*)($(›'(.*$%;;&#›<P*›#<()'(#<›%#*=›<A*#"-%I%#(M
-]%<"-*%4*"B%&<*1222*%'().%,(,*%#*ł,-"#.*(IO($<(.*<A›,*P(")M

- 5^C)· ")(*."›-P*&,(),M
- F23*"J(*)"#J(*52N 0FM*
- _03*&#.()*"J(*52M
- EE3*;"-(M*
- @"-4*&,›#J*"-%#(M
- @"-4*›#*O)›'"<(*)(,›.(#$(M
- +,-"#.*.›,<)›B&<›%#*V"--*")("',M*[%;(*;%)(*"44($<(.M*`[&)J(,a*$"#*$"&,(*"*-%$"-*$)›,›,M

- [$A%%-*B%")..,*A"'(*"*,›J#›4›$"#<*)%-(*›#*
)("$A›#J*O")(#<,*"#.*,<&.(#<,*"->T(M
- c(,<›J;"<›d›#J,&B,<"#$(*&,(*›#*<A(*$%#<(I<*%4*
".%-(,$(#<*B(A"'›%&)M
- +.(#<›4P›#J*&#"$$(O<"B-(*B(A"'›%&),M

- [&OO%)<>#J*,<&. (#<,*>#* ; "T>#J*A("-<A>()* $A%>$(,Q
  - 9?G89*$&))>$&-")*%O<>%#,M
  -]A(* e c?GHM

- [&B,<"#$(*&,(*;"#"J(;(#<Q
  - W›J)"<›%#*4)%;*O&#›<›'(*<%*$%#,<)&$<›'(*›#<()'(#<›%#M*
  - R)%B-(;"<›$*$%#$&))(#<*B(A"'›%&)"-*.›,%).(),M*

Naloxone

- YD022*T><,*.>,<)>B&<(.*"$)%,,*+,-"#.M
- R)%'>#$>"-*)>,T*",,(,,;(#<*N A>JA*,$A%%-,*#%<*"*A>JA()*)>,T*-%$"<>%#M*
- 9A%>$(*<%*A"'(*T><*>,*4%)*,$A%%-Q
  - K((.*4%)*T></,7M
  - K((.*4%)*<)">#>#JM

]%<"- '›,›<,*	6C02:
+#›<›"-*'›,›<,	02:
K& ; B()*%4 %'().%,(,*"<*,›<(* " ; %#J*'›,›<%),*<%*,›<(	66D
K& ; B()*%4*%'().%,c	

#J*

- 9"##"B›,

Paul Hasselback MD MSc FRCPC
250.739.6304
Medical Health Officer
Central Vancouver Island
paul.hasselback@viha.ca